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ABSTRACT 
It has been known for decades that cancer cells exhibit enhanced rates of Glucose uptake and glycolysis. Rapidly growing Tumor cells display 
remarkably different metabolic autonomy from the tissues which they are derived. Tumor cells alter their metabolism to support growth and 
proliferation. In this study, we have re-examined the metabolism in tumor cells and have made an attempt to bring together the major 
contributions made to this topic till date. This review in particular highlights the altered metabolism in the high energy demanding tumour 
cells, genetic changes that alter tumour cell metabolism and the role of metabolic microenvironments that may promote maligna nt progression.  
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INTRODUCTION 
Over the past few decades, increased researches related to 
the metabolic adaptations of the cancer cells has resulted 
in the augmentation of evidences that suggest an 
association of the several pathways of human metabolism 
with the cancer cells¹ʼ²ʼ³. Tumour cells are less specialised 
than the normal cells´ which help them ignore signals to 
sustain an uncontrolled divisionµ and defy apoptosis 
mediated particularly by oxidative damage¶. For a cell to 
divide rapidly, it must be nutrient hungry of the major 
metabolically demanding macromolecules viz. 
carbohydrates, proteins, lipids and nucleic acids. However, 
these essential nutrients are only present in 
concentrations that are spatially and temporarily 
heterogenous·. Therefore, it is required that the cancer 
cells adapt to this stressful microenvironment of the 
growing tumour. It is this anabolic drive that redesigns the 
tumour cell’s metabolic pathway for its better survival and 
growth. 
Carbohydrate come from nearly all food sources in our diet 
and is eventually broken down into glucose by enzymes in 
the small intestine; which are later absorbed into the blood 
stream through the intestinal walls by the villi. Glucose 
being the body’s main energy source, most of the calories 
are derived from the carbohydrates. The catabolism of 
carbohydrates to yield ATP in a normal cell is associated 
with pathways such as Glycolysis or Embden-Meyerhoff 
Pathway, Oxidation of pyruvate, the Citric acid cycle or the 
Kerb’s Cycle, Pentose Phosphate Pathway, Glycogenolysis, 
Glycogenesis and Gluconeogenesis. 
The application of computer-aided tomography (CAT) in 
combination with positronemission tomography (PET) 
imaging technique using the glucose analogue tracer 
fluorodeoxyglucose (FdG) has demonstrated that most 
cancer cells show significantly increased glucose 
uptake¸־¹³.This is because anabolic pathways branching off 
from glycolysis produces some biosynthetic intermediates 
such as amino acids, lipids and nucleotide precursors¹´. In 
a cancer cell, the demand for these products is relatively 
high owing to its nature of rapid growth. When glycolytic 
flux through these pathways increases, glucose uptake 
must also increase alongside to maintain normal ATP 
levels. As per reports, by the time a normal cell would take 
to produce 36 ATP from per glucose, the normoxic cancer 
cell would utilize 11 molecules of glucose to produce 56 
ATP from it, whereas the anoxic cancer cell would generate 
26 ATP from 13 glucose molecules¹µ. 
This review aims to describe the role of altered glucose 
metabolic pathway in the high energy demanding tumour 
cells as described by the Warburg effect with a particular 
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emphasis on the role played by hypoxia inducible factor 
(HIF1), pH and high lactate concentration in 
tumour cell metabolism. It is rather interesting to know 
how tumour cells shift from normal cellular respiration to 
an inefficient glucose metabolism for meeting their ATP 
needs. To look at it from a different perspective, the 
increased uptake and altered metabolism of glucose is 
actually a solution to the constraints put by the 
environment on the growth of tumour cells. 
The Crabtree effect 
 English biochemist Herbert Grace Crabtree asserts that 
the presence of glucose in normal cells increases the rate of 
respiration or has no effect on oxygen consumption. 
However, in the cancer cells, the presence of glucose 
decreases the oxygen uptake. This inhibition in respiration 
is known as the Crabtree effect. 
The mechanism by which the Crabtree effect operates is 
unknown. Yet, several mechanisms have been suggested to 
explain the Crabtree effect in tumour cells. 
 Pi levels tend to decrease after the addition of glucose 
in tumour cells¹¶. It has been proposed that a 
decrease in Pi triggers the Crabtree effect in some 
tumour cells¹·. 
 A decrease in the cytosolic pH can decrease the rate 
of synthesis of ATP by the mitochondria thereby 
inducing the Crabtree effect¹¸. 
 Increased mitochondrial Ca2 + uptake in response to 
glucose may lead to the inhibition of the ATP 
synthase inducing a decrease of respiration¹¹՚²ºʼ²¹. 
An increase in calcium levels in mitochondria can 
increase the association of the inhibitory subunits of 
F1F0 to the ATP synthetase thereby inhibiting coupled 
respiration ²². 
 It is reported that the metabolite Fructose-1, 6-
biphosphate participates in the e stablishment of the 
Crabtree effect. It links glycolysis to the inhibition of 
respiration by inhibiting mitochondrial respiratory 
rate at the level of respiratory complexes III and IV²³. 
 The metabolism of glucose increases the production 
of reactive oxygen species that depresses respiration 
by damaging the mitochondrial membranes²´. 
 The overproduction of a particular hexose 
monophosphate viz. Glucose-6-phosphate releases 
the mitochondria-bound hexokinase II. The 
dissociation of it promotes the acceleration of 
adenine nucleotide fluxes from the outer membrane 
of mitochondria thereby inhibiting respiration²µ.  
 When glycolysis is overactive, the enzymes 
phosphoglycerate kinase and pyruvate 
kinasecompete with the mitochondria for free 
cytosolic ADP uptake²¶՚²·. ADP being a substrate   
of the oxidative phosphorylation, would limit the ATP 
synthase and consequently respiration would be 
decreased. 
The Warburg effect 
Otto Heinrich Warburg worked on glycolysis and showed 
that the cancer cells exhibited a reversed Pasteur effect i.e., 
in a tumour cell, a substantial amount of pyruvate is 
reduced to lactate even in the presence of oxygen instead 
of being directed into the mitochondria to produce ATP by 
oxidative phosphorylation ²¸. Cancer cells are, therefore, 
compelled to rely on inefficient mode of synthesizing ATP 
as it produces only 2 ATPs per molecule of glucose rather 
than the conventional respiration that produces 
approximately 36 ATPs per molecule of glucose. It is ironic 
to realise that the tumour cells that require a huge supply 
of ATP for its rapid growth, would switch to aerobic 
glycolysis that produces significantly lesser molecules of 
ATPs than that is required. As a result, to meet their 
increased energy needs, biosynthesis and redox needs 
more glucose molecules are taken up. A possible reason as 
to why cancer cells re-programme their metabolic pathway 
is to produce other metabolic end products to support 
their uncontrolled growth and proliferation in low oxygen 
tension during the process of tumour progression. 
Warburg misinterpreted his own early observations 
stating that respiration must be damaged in cancer cells as 
even high levels of O2 are unable to suppress lactic acid 
production in them²¹. Warburg hypothesized that cancer 
cells develop a defect in mitochondria that leads to 
impaired aerobic respiration and a subsequent reliance on 
glycolytic metabolism³º. However future work has shown 
that mitochondrial function is not always impaired in 
cancer cells³¹. However, in later studies it was reported 
that mitochondrial defects are rare³².  
Metabolic pathways in cancer cells 
MYC - HIF- VHL 
With respect to glycolysis, overexpressed MYC have shown 
to collaborate with HIF in the activation of several glucose 
transporters and glycolytic enzymes such as LDHA and 
PDK1.MYC induces the splicing factors that produce 
PKM2³². PKM2 converts PEP to pyruvate in aerobic 
glycolysis thereby further underscoring the role of MYC in 
the aerobic glycolysis process. In RCCs, MYC appears to 
collaborate with activated HIF2α to confer tumorigenicity. 
The HIF1 and HIF2 complexes are the major transcription 
factors that are responsible for the   gene expression 
changes during the cellular response to low oxygen 
conditions. They are heterodimers that are composed of 
the constitutively expressed HIF1β (also known as ARNT) 
subunit, and either the HIF1α or the HIF2α (also known as 
EPAS1) subunits, which are rapidly stabilized on exposure 
to hypoxia. HIF1α is ubiquitously expressed, whereas the 
expression of HIF2α is restricted to a more limited subset 
of cell types³³. HIF1 can also be activated under normoxic 
conditions by oncogenic signalling pathways, including 
PI3K³´’³µ and by mutations in tumour suppressor proteins 
such as VHL³¶’³·, SDH ³¸ and FH³¹. Once activated, HIF-1 
amplifies the transcription of genes encoding glucose 
transporters and most glycolytic enzymes, increasing the 
capacity of the cell to carry out glycolysis´º. In addition, 
HIF-1 transactivates the gene encoding pyruvate 
dehydrogenase kinases 1(PDK1), which inactivate the 
mitochondrial pyruvate dehydrogenase complex and 
thereby reduce the flow of glucose-derived pyruvate into 
the tricarboxylic acid (TCA) cycle´¹՚´²՚´³. HIF-1 induction 
can also be triggered by the mitochondria themselves. 
Accumulation of krebs cycle substrates might serve as a 
signal for stimulation of glycolysis when mitochondrial 
respiration in tumor cells downregulated ´´.   
Under normoxic conditions HIF1α subunits undergo 
oxygen-dependent hydroxylation by prolyl hydroxylase 
enzymes, which results in their recognition by the tumour 
suppressor protein VHL. VHL is an E3 ubiquitin ligase that 
normally mediates proteosomal degradation of HIF1α. In 
RCCs, the loss of VHL results in the non-hypoxic expression 
of HIF1α and HIF2α´µ. 
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 The role of HIF1 is not restricted to upregulation of the 
enzyme stimulating glucose utilization. HIF1 stimulates the 
conversion of glucose to pyruvate and lactate by 
upregulating glucose transporter (GLUT) isoform 
1(GLUT1) hexokinase and lactate dehydrogenase A 
(LDHA) as well as the lactate extruding enzyme 
monocarboxylate transporter 4 (MCT4)´¶՚´·. 
PI3K - ATK1 – mTOR 
Augmentation of this pathway by mutations activating 
PI3K or eliminating negative regulators like PTEN 
comprises a prevalent category of mutation in human 
cancer´¸. The PI3K pathway is activated by mutations in 
tumour suppressor genes, such as PTEN, mutations in the 
components of the PI3K complex itself or by aberrant 
signalling from receptor tyrosine kinase ´¹. 
AKT1 is an important driver of the tumour glycolytic 
phenotype and stimulates ATP generation through 
multiple mechanisms, ensuring that cells have the 
bioenergetic capacity required to respond to growth 
signalsµº’µ¹. AKT1 stimulates glycolysisby increasing the 
expression and membrane translocation of glucose 
transporters and by phosphorylating key glycolytic 
enzymes, such as hexokinase and phosphofructokinase 2 
(also known as PFKFB) µ². The increased and prolonged 
AKT1 signalling that is associated with transformation 
inhibits forkhead box subfamily O (FOXO) transcription 
factors, resulting in a host of complex transcriptional 
changes that increase glycolytic capacity µ³.  AKT1 also 
activates ectonucleoside triphosphate diphosphohydrolase 
5 (ENTPD5), an enzyme that supports increased protein 
glycosylation in the endoplasmic reticulum and indirectly 
increases glycolysis by creating an ATP hydrolysis cycle µ´. 
Although AKT function independently of HIF1 to induce 
aerobic glycolysis µµ՚µ¶, it can also increase the activity of 
HIF1, further enhancing induction of glycolysisµ·. 
AKT1 strongly stimulates signalling through the kinase 
mTOR by phosphorylating and inhibiting its negative 
regulator tuberous sclerosis 2 (TSC2; also known as 
tuberinµ¸. mTOR functions as a key metabolic integration 
point, coupling growth signals to nutrient availability. 
Activated mTOR stimulates protein and lipid biosynthesis 
and cell growth in response to sufficient nutrient and 
energy conditions and is often constitutively activated 
during tumorigenesisµ¹. At the molecular level, mTOR 
directly stimulates mRNA translation and ribosome 
biogenesis, and indirectly causes other metabolic changes 
by activating transcription factors such as HIF1 even under 
normoxic conditions. 
AMPK 
The tumour suppressor gene STK11 codes for liver kinase 
B1 (LKB1) which in turn activates AMPK. Biochemically, 
AMPK opposes the effects of AKT1 and functions as an 
inhibitor of mTOR. The loss of AMPK signalling allows the 
activation of mTOR and HIF1, and therefore might also 
support the shift towards glycolytic metabolism. AMPK 
functions as a metabolic checkpoint, regulating the cellular 
response to energy availability. During periods of energetic 
stress, AMPK becomes activated in response to an 
increased AMP/ATP ratio. Tumour cells must overcome 
this checkpoint in order to proliferate in response to 
activated growthsignalling pathways, even in a less than 
ideal microenvironment¶º. 
 
Activated RAS 
It was recently reported that depriving colon carcinoma 
cells of glucose increases the mutation rate of RAS, which, 
thus activated, facilitates glucose import through induction 
of GLUT1 (also known as SLC2A1), an important glucose 
transporter¶¹. In a multistep, multigene transformation of 
human breast epithelial cells, it was documented that the 
initial transformation of normal epithelial cells by viral 
oncogenes and telomerase reverse transcriptase is 
associated with increased mitochondrial function; with 
activated KRAS as the final reaction step in this model, the 
transformed cells exhibit the Warburg effect through high 
conversion of glucose to lactate ¶². It is notable that 
activated RAS has been proposed to induce MYC activity 
and enhance non-hypoxic levels of HIF1, although the 
precise mechanisms remain to be established ¶³՚¶´. 
p53 and OCT1 
p53 is a cellular regulator and transcriptional factor with 
tumour suppressor properties which is an important 
regulator of cell death and replicative senescence in 
response to oncogenic stress¶µ. p53 activates the 
expression of hexokinase 2 (HK2), which converts glucose 
to glucose-6-phosphate (G6P)¶¶. G6P then either enters 
glycolysis to produce ATP, or enters the pentose phosphate 
pathway (PPP).Activation of SCO2 (which regulates the 
cytochrome c oxidase complex) by p53 increases the 
efficiency of mitochondrial respiration¶·. Conversely, p53 
suppression of phosphoglycerate mutase 2 (PGAM2) and 
activation of tumour protein 53-induced glycolysis and 
apoptosis regulator (TIGAR), which has 2,6-fructose 
bisphosphatase activity and depletes PFK1 of a potent 
positive allosteric ligand, suppresses glycolysis and favours 
increased NADPH production by the pentose phosphate 
pathway¶¸՚¶¹. Wild-type p53 also supports the expression 
of PTEN, which inhibits the PI3K pathway, thereby 
suppressing glycolysis·º. 
OCT1 (also known as POu2F1) is a transcription factor, the 
expression of which is increased in several human cancers, 
and it may cooperate with p53 in regulating the balance 
between oxidative and glycolytic metabolism·¹՚. Data from 
studies of knockout mice and human cancer cell lines show 
that OCT1 regulates a set of genes that increase glucose 
metabolism and reduce mitochondrial respiration. One of 
these genes encodes an isoform of PDK (PDK4) that has the 
same function as the PDK enzymes that are activated by 
HIF1·². 
Tumour microenvironment 
Hypoxia – Although a pre-malignant lesion such as a polyp 
or carcinoma are often characterised as highly 
vascularised, the hyperplastic epithelia are physically 
separated from their blood supply by a basement 
membrane. In the early phases of tumour formation, 
uncontrolled cell proliferation shifts tumour cells away 
from the blood vessels and therefore are deprived from the 
supply of oxygen and nutrients. At this stage, it is only 
through diffusion across the basement membrane and 
through the peripheral tumour-cell layers that oxygen and 
nutrients reach the inner cells of a non-vascularised 
tumour. This diffusion and consumption process were 
modelled through reaction-diffusion equations which 
proved that as the distance from a blood vessel increases, 
the oxygen concentration decreases such that oxygenated 
cells were limited to a distance of less than 150 μm from a 
blood vessel·³. In neoplastic cell populations, low 
concentrations of oxygen seem to be the first substrate 
limitation, as reaction-diffusion models have proved 
empirically that the decline of pO2is more rapid as the 
distance from the blood vessels increases ·´ֿ־··. 
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In studies with tumour xenografts using a magnetic-
resonance imaging technique that is sensitive to 
oxygenation status·¸ and using microelectrodes·¹, it was 
shown that oxygen delivery to tumours is inconsistent. 
Oxic-hypoxic cycles in tumours may occur at intervals of 
minutes¸º, hours ¸¹ or even days¸². These cycles are 
probably due to a range of physiological mechanisms. It 
has been suggested that oxic-hypoxic fluctuations in the 
penumbral region of pre-malignant tumours favours 
maintenance of metabolic activities in the absence of 
oxygen. 
A hypoxic microenvironment induces tumour growth by 
activating the transcription factor hypoxia-inducible factor 
1 (HIF1). HIF1 regulates genes that are responsible for the 
expression of most glycolytic enzymes such as 
hexokinases, regulation of tumour pH, angiogenesis and 
the expression of glucose transporters GLUT1 and 
GLUT3¸³. Angiogenesis is brought about by the expression 
of vascular endothelial growth factor (VEGF) when 
induced by HIF1. This facilitates the formation of new 
blood vessels in the tumour cells previously separated by 
the basement membrane thereby establishing a link for the 
supply of essentials for their growth.  
Under normoxic conditions the ODD (Oxygen-dependent 
degradation) domain of HIF1α is hydroxylated by prolyl 
hydroxylases (PHDs) followed by subsequent 
ubiquitination by Von-Hippel Lindau (VHL), thereby 
degrading HIF1α and rendering it inactive¸´־¸¶. Also, 
several factors inhibiting HIF1 (FIH1) gets activated under 
normoxic conditions. FIH1 hydroxylates an asparagine 
residue of HIF α following which, anasparaginyl 
hydroxylation blocks the interaction of HIF1α with 
transcriptional factors p300 and CBP, thereby suppressing 
HIF1α’s transactivational activity. However, under hypoxic 
conditions, HIF1α becomes stable. Since oxygen is a 
substra te of both FIH1 and PHDs, an oxygen deprived 
condition activates HIF1¸·. Upon which, HIF1α interacts 
with HIF1β and forms a heterodimer HIF1¸¸. HIF1 binds to 
its cognate DNA sequence, the hypoxic responsive element 
(HRE) and ultimately initiates the expression of glycolysis, 
metastasis, angiogenesis¸¹־ ¹¹. 
Hypoxia also inhibits mTOR signalling¹²՚¹³. Albeit mTOR 
inhibition results in tumour suppression, evidences assert 
that mTOR inhibition increases the tolerance to hypoxia 
and promotes tumour cell survival during metabolic stress. 
In certain microenvironment, tumour cells have been 
found to benefit from moderate mTOR activity¹´. mTOR 
inhibition have been found to induce autophagy in tumour 
cells¹µ. 
pH: 
 An increase in the rate of glycolysis results in the increase 
in the production of glycolytic byproducts such as lactate 
and H+. This makes the intracellular environment of the 
tumour cells highly acidic and shown to induce 
apoptosis¹¶. In order to overcome this and maintain 
homeostasis, cancer cells efflux lactate and H+by 
monocarboxylate transporters (MCTs) and Na+/H+ 
exchangers (NHEs) respectively¹·՚¹¸, making the 
extracellular pH now highly acidic. Numerous studies have 
shown that the extracellular pH of tumour cells can reach a 
pH value as low as ≤ 6.¹¹՚¹ºº. Only through adaptations to 
this low pH microenvironment will an avascular pre-
invasive tumour transform into a malignant invasive 
tumour with patent vasculature ¹º¹. The low extracellular 
pH values under some conditions induces migration and 
invasion ¹º²՚¹º³. Such an induction mechanism might 
involve the metalloproteinases and cathepsins, which 
promote the degradation of the extracellular matrix and 
basement membranes¹º´՚¹ºµ. 
Fate of lactate produced in cancer cells 
An increase in the rate of glycolysis in cancer cells 
increases the production of glycolytic byproducts viz. 
lactate and H+ making the intracellular region highly acidic. 
Hypoxic cells produce enormous amounts of lactate using 
two key enzymes: pyruvate dehydrogenase kinase (PDK1) 
that inhibits pyruvate dehydrogenase (PDH) from 
converting pyruvate to acetyl-CoA; and Lactate 
dehydrogenase kinase A (LDHA) which converts pyruvate 
to lactate¹º¶ . In order to maintain homeostasis, these 
products need to be exported to the extracellular space. 
The cell exports lactate and H+by monocarboxylate 
transporters (MCTs) and Na+/H+ exchangers (NHEs) 
respectively, making the extracellular environment of the 
tumour acidic. The oxygenated cells in the vicinity then 
removes lactate from the extracellular fluid using MCT1. 
Lactate is now converted back to pyruvate for further 
oxidation using the LDBH isoform, thereby conserving 
glucose for use by the hypoxic cells. 
Redox balance of cancer cells 
The net physiological balance between reducing and 
oxidizing equivalents within the cell is maintained due to 
reduction/oxidation (redox) homeostasis in it ¹º·. In a 
normal healthy tissue, the production of Reactive oxygen 
species (ROS) and Reactive Nitrogen Species (RNS) are 
well-regulated to help maintain homeostasis ¹º¸. 
 ROS are tumorigenic by their ability to increase cell 
proliferation and migration, but also by inducing genetic 
lesion that can initiate tumorigenicity and sustain 
subsequent tumor progression ¹º¹. ROS at low levels have 
been reported to increase cell proliferation and survival 
through the post-translational modification of kinases and 
phosphatases¹¹º’՚¹¹¹. At moderate levels, ROS induces the 
expression of stress-responsive genes such as HIF1Α, 
which in turn trigger the expression of proteins providing 
prosurvival signals, such as the glucose transporter GLUT1 
(also known as SLC2A1) and vascular endothelial growth 
factor (VEGF)¹¹²՚¹¹³. At high levels, ROS can cause damage 
to macromolecules, including DNA; induce the activation of 
protein kinase Cδ (PKCδ), triggering senescence¹¹´՚¹¹µ 
and/or cause permeabilization of the mitochondria, 
leading to the release of cytochrome c and apoptosis¹¹¶՚¹¹· 
and activate pathways such as PI3K andmitogen-activated 
protein kinase/extracellular signal–regulated kinase 
(MAPK/ERK)] and transcription factors such as HIF and 
nuclear factor kB (NF-kB) necessary for tumorigenesis. 
To counter such oxidative stress, a cell uses antioxidants 
that prevent ROS from accumulating at high levels.The 
primary antioxidant enzymes in cells include superoxide 
dismutase (SOD), glutathione peroxidase (GPX), and 
catalase (CAT). Other antioxidant enzymes such as 
thioredoxin (TRX), glutaredoxin (GRX), and peroxiredoxin 
(PRX) also contribute to cellular protection against 
oxidation¹¹¸. 
Mitochondria and cytosolic NADPH oxidases 
(NOXs)produces O2- from the one-electron reduction of 
oxygen ¹¹¹ and convert it into H2O2 by the enzymatic 
activity of superoxide dismutase 1 or 2 (SOD), which are 
localized to the cytosol or mitochondrial matrix, 
respectively.The dismutation of superoxide produces 
hydrogen peroxide. Hydrogen peroxide is a more stable 
ROS and it is permeable to cellular membranes. Despite 
being a relatively weak oxidizing agent; H2O2at high levels 
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can generate hydroxyl radicals through the Fenton 
reaction ¹²º and prove to be cytotoxic.H2O2 is subsequently 
detoxified to water by the enzymatic activity of 
mitochondrial and cytosolic peroxiredoxins (PRXs), which, 
as a consequence, undergo H2O2-mediated oxidation of 
their active-site cysteines¹²¹. Thioredoxin (TRX), 
thioredoxin reductase (TR), and the reducing equivalent 
NADPH reduce oxidized PRXs to complete the catalytic 
cycle¹²². Glutathione peroxidases (GPXs) can also convert 
H2O2 to water in the mitochondrial matrix and cytosol 
through H2O2-mediated oxidation of reduced glutathione 
(GSH) ¹²³. Glutaredoxin (GRX) can directly reduce H2O2 in a 
catalytic manner, using reducing power provided by 
NADPH, GSH, and glutathione reductase ¹²´ . Glutathione 
reductase (GR) and NADPH reduce oxidized glutathione 
(GSSG) back to GSH. Additionally, catalase (CAT), an 
abundant antioxidant in peroxisomes, can detoxify H2O2 to 
water without any cofactors. 
During the process of tumorigenesis, loss of the tumour 
suppressor gene TSC2 makes mTOR hyperactivated ¹²µ. A 
hyperactivated mTOR leads to the upregulation of 
translation and increased ROS production. Loss of tumour 
suppressor retinoblastoma (RB) fails to counter ROS due 
to lack of antioxidant response and the cell undergoes 
apoptosis¹²¶. Similarly, loss of tumour suppressor gene 
PTEN hyperactivates AKT1 which inactivates FOXO and 
increases oxidative stress¹²·. 
NRF2 is an antioxidant transcription factor which 
upregulates the expression of several antioxidant and 
detoxifying molecules. p53 has been reported to promote 
the stabilization of the transcription factor nuclear factor 
(erythroidderived 2) -related factor-2 (NRF2) through its 
target gene cyclin-dependent kinase inhibitor 1A 
(CDKN1A). When ROS levels are low, NRF2 binds to Kelch-
like ECH-associated protein 1 (KeAP1)¹²¸. Critical cysteine 
residues within KEAP1 can undergo oxidation, succination, 
and glutathionylation, thereby inhibiting the KEAP1-NRF2 
interaction, leading to the proteasomal degradation of 
NRF2¹²¹. However, under oxidative stress, p53 is activated 
and stimulates expression of p21 by CDKN1A.  Once 
activated, NRF2 induces the transcription of many 
antioxidant proteins including GPXs and TXNs as well as 
enzymes involved in GSH sy nthesis and cysteine import 
through the cysteine/ glutamate antiporter. Furthermore, 
to maintain the antioxidant capacity of GPXs and TXNs, 
NADPH is required. NRF2 plays an important role in 
activating enzymes that increase cytosolic NADPH levels. 
NRF2 also regulates the serine biosynthesis pathway, 
generating NADPH in the mitochondria, which is critical 
for redox balance under hypoxic conditions¹³º՚¹³¹. 
Therefore, inactivating NRF2 or disabling antioxidant 
proteins in cancer cells would allow for the accumulation 
of excessive amounts of ROS to levels that initiate toxicity 
and reduce tumorigenesis¹³²’¹³³. 
In neurodegenerative diseases such as Parkinson’s disease, 
DJ1 promotes antioxidant responses by stabilizing 
NRF2¹³´՚¹³µ. Loss of DJ1 function leads to elevated 
oxidative stress in the brain and neuronal cell death and 
also to regulate the tumour suppressor PTEN and in turn 
stimulate AKT1 activity ¹³¶.  
GSH is another important antioxidant that controls the 
redox balance of sub-cellular components¹³·. Although 
glutamine is not an essential amino acid in a normal cell, as 
mentioned earlier, cancer cells are critically dependent on 
it. MYC has been reported to promote the uptake of 
glutamine by inducing the expression of glutamine 
transporters SLC5A1 and SLC7A1. MYC also inhibits the 
expression microRNA-23A and microRNA-23B to increase 
glutaminase 1 (GLS1); the first enzyme of 
glutaminolysis¹³¸. MYC also enhances the antioxidant 
capacity by producing NADPH with the expression of the 
PKM2 isoform via. Pentose Phosphate pathway (PPP) and 
by the synthesis of GSH through glutaminolysis.De novo 
synthesis of GSH is also achieved through the upregulation 
of Glutaminase 2 (GLS2) by p53¹³¹.  
CONCLUSION 
Despite the myriad of adaptations that the tumour cells 
undergo for its faster growth and better survival, there lies 
one distinct difference between the normal cells and the 
tumour cells that makes them resort to the Warburg effect 
and aerobic glycolysis. In the presence of growth factors, a 
normal cell would undergo quiescence when deprived of 
nutrients but a cancer cell, on the other hand, in the 
presence of growth factors is stimulated in a way that 
demands the supply of ATP and an upregulation of 
nutrients along with it. The three important steps that 
balance the metabolic adaptations of these tumour cells 
are: increased ATP production, ample macromolecular 
biosynthesis and maintaining a redox balance. The basis of 
the resistance that a tumour cells exhibits to both 
radiotherapeutic and chemotherapeutic agents lies in its 
unsual metabolic pathway. To which, a reversion to a 
normal metabolic pathway would make these cells slows in 
progression and increase its response to these agents. HIF-
1 and PI3K/Akt/ mTOR pathways have an important role 
in cancer metabolism and the Warburg effect. 
Development of cancer cells depends on various factors. So 
it is very difficult to establish a generalized cancer 
treatment. But our understanding of cancer cell 
metabolism evolved continuously because of advances in 
technologies. Thus, survival and quality of life will be 
improved for cancer patients.  
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